Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1987 3
1988 7
1989 5
1990 5
1991 4
1992 2
1993 10
1994 4
1995 8
1996 12
1997 13
1998 8
1999 3
2000 8
2001 13
2002 14
2003 17
2004 13
2005 16
2006 10
2007 12
2008 13
2009 23
2010 8
2011 21
2012 11
2013 12
2014 15
2015 18
2016 10
2017 11
2018 15
2019 19
2020 14
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

358 results
Results by year
Filters applied: . Clear all
Page 1
Advances in cancer immunotherapy 2019 - latest trends.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Kruger S, et al. Among authors: endres s. J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. J Exp Clin Cancer Res. 2019. PMID: 31217020 Free PMC article. Review.
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.
Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Benmebarek MR, et al. Among authors: endres s. Int J Mol Sci. 2019 Mar 14;20(6):1283. doi: 10.3390/ijms20061283. Int J Mol Sci. 2019. PMID: 30875739 Free PMC article. Review.
Determinants of response and resistance to CAR T cell therapy.
Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S. Lesch S, et al. Among authors: endres s. Semin Cancer Biol. 2020 Oct;65:80-90. doi: 10.1016/j.semcancer.2019.11.004. Epub 2019 Nov 6. Semin Cancer Biol. 2020. PMID: 31705998 Review.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Geiger M, Stubenrauch KG, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, Lauer ME, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein C. Geiger M, et al. Among authors: endres s. Nat Commun. 2020 Jun 24;11(1):3196. doi: 10.1038/s41467-020-16838-w. Nat Commun. 2020. PMID: 32581215 Free PMC article.
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M, Koenig LM, Formisano S, Boehmer DFR, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhöfler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger FS, Rothenfusser S. Ruzicka M, et al. Among authors: endres s. Leukemia. 2020 Apr;34(4):1017-1026. doi: 10.1038/s41375-019-0639-x. Epub 2019 Nov 18. Leukemia. 2020. PMID: 31740809 Free PMC article.
5'-Triphosphate RNA is the ligand for RIG-I.
Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. Hornung V, et al. Among authors: endres s. Science. 2006 Nov 10;314(5801):994-7. doi: 10.1126/science.1132505. Epub 2006 Oct 12. Science. 2006. PMID: 17038590 Free article.
Therapie allergischer Erkrankungen – Stand und Ausblick.
Bieber T, Endres S. Bieber T, et al. Among authors: endres s. Drug Res (Stuttg). 2020 Nov;70(S 01):S5. doi: 10.1055/a-1119-2582. Epub 2020 Nov 17. Drug Res (Stuttg). 2020. PMID: 33202464 German. No abstract available.
Müller-Werdan U, Endres S. Müller-Werdan U, et al. Among authors: endres s. Drug Res (Stuttg). 2019 Nov;69(S 01):S4. doi: 10.1055/a-0982-4982. Epub 2019 Nov 15. Drug Res (Stuttg). 2019. PMID: 31731297 German. No abstract available.
358 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page